Martin J. Gilligan
Corporate Officer/Principal chez PHATHOM PHARMACEUTICALS, INC.
Profil
Martin J.
Gilligan is currently the Chief Commercial Officer at Phathom Pharmaceuticals, Inc. Previously, he worked as the VP-Inflammation & Immunology at Celgene Corp.
He holds an MBA from Rutgers State University of New Jersey and an undergraduate degree from Providence College.
Postes actifs de Martin J. Gilligan
| Sociétés | Poste | Début |
|---|---|---|
| PHATHOM PHARMACEUTICALS, INC. | Corporate Officer/Principal | 06/01/2020 |
Anciens postes connus de Martin J. Gilligan
| Sociétés | Poste | Fin |
|---|---|---|
| CELGENE | Corporate Officer/Principal | - |
Formation de Martin J. Gilligan
| Rutgers State University of New Jersey | Masters Business Admin |
| Providence College | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| PHATHOM PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
